LSE statement23 Feb 2021 20:56
Roby Zomer, Managing Director and CEO of MGC Pharma commented: “We are delighted to be celebrating MGC Pharma’s London Stock Exchange listing today, a pivotal moment in the Company’s journey. We are very proud that following the significant progress and achievements of our company to date, we will be the first medicinal cannabis company to list on London Stock Exchange's Main Market, something we have been working towards for over 18 months, realising our strategic ambition to be closer to our operations in Europe with greater access to key UK and European strategic funds and investors.”
“We are already seeing the benefits of this decision, with the strong show of support from a number of leading UK institutional funds, family offices and sophisticated investors for the Placing. The funds will primarily be used to support the Company’s growth ambitions and key clinical research programs for our leading products, as we continue to expand our manufacturing capabilities, fast track our key clinical trials, increase our product range, and expand into new and existing key markets.
“We would like to thank London Stock Exchange for its warm welcome, and our employees and shareholders who have enabled us to get to this point in our growth. We look forward to their continued support as we commence the next phase of our growth strategy.”